Chimerix logo

ChimerixNASDAQ: CMRX

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

11 April 2013

Next earnings report:

28 February 2025

Last dividends:

N/A

Next dividends:

N/A
$77.33 M
-87%vs. 3y high
41%vs. sector
-vs. 3y high
-vs. sector
-94%vs. 3y high
28%vs. sector
486.33
-41%vs. 3y high
98%vs. sector

Price

after hours | Wed, 20 Nov 2024 23:23:55 GMT
$0.86-$0.04(-4.47%)

Dividend

No data over the past 3 years
$26.00 K$310.60 K
$26.00 K-$22.88 M

Analysts recommendations

Institutional Ownership

CMRX Latest News

Chimerix (CMRX) Reports Q3 Loss, Lags Revenue Estimates
zacks.com07 November 2024 Sentiment: NEGATIVE

Chimerix (CMRX) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.27 per share a year ago.

Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com18 October 2024 Sentiment: POSITIVE

DURHAM, N.C., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on October 16, 2024, the Compensation Committee of Chimerix's Board of Directors granted an inducement award to a new employee of non-statutory stock options to purchase up to a total of 130,000 shares of Chimerix's common stock. The Compensation Committee of Chimerix's Board of Directors approved the award as an inducement material to the new employee's employment in accordance with Nasdaq Listing rule 5635(c)(4).

Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com30 August 2024 Sentiment: POSITIVE

DURHAM, N.C., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on August 20, 2024, the Compensation Committee of Chimerix's Board of Directors granted an inducement award to a new employee of non-statutory stock options to purchase up to a total of 150,000 shares of Chimerix's common stock. The Compensation Committee of Chimerix's Board of Directors approved the award as an inducement material to the new employee's employment in accordance with Nasdaq Listing rule 5635(c)(4).

Chimerix (CMRX) Reports Q2 Loss, Misses Revenue Estimates
zacks.com13 August 2024 Sentiment: NEUTRAL

Chimerix (CMRX) came out with a quarterly loss of $0.23 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.21 per share a year ago.

Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com05 July 2024 Sentiment: POSITIVE

DURHAM, N.C., July 05, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on July 1, 2024, the Compensation Committee of Chimerix's Board of Directors granted inducement awards to two new employees of non-statutory stock options to purchase up to a total of 120,000 shares of Chimerix's common stock. The Compensation Committee of Chimerix's Board of Directors approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing rule 5635(c)(4).

Chimerix to Participate in Fireside Chat at Jefferies Global Healthcare Conference
globenewswire.com30 May 2024 Sentiment: POSITIVE

DURHAM, N.C., May 30, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Andriole, Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 3:00 p.m. ET.

Chimerix: Tackling A Strong Unmet Need With Promising Data
Seeking Alpha01 March 2024 Sentiment: POSITIVE

Chimerix, Inc. is a biotech company focused on developing novel treatments for high-grade glioma and other therapies. Their main clinical asset, doraviprone, has shown promising results in treating H3 K27M-mutated diffuse midline glioma. The company has a strong financial position with over $200 million in assets and a runway of 2+ years, making it an attractive investment for those with a longer-term outlook.

Chimerix: Dangerous Road, Thesis Intact
Seeking Alpha08 September 2023 Sentiment: POSITIVE

Chimerix meets financial expectations during Q2, 2023 earnings call. Investment thesis for Chimerix focuses on its ONC201 study expected to read out in 2026. Company has high risk of loss despite expected $200 million in liquidity by the end of 2023.

Chimerix, Inc. (CMRX) Q2 2023 Earnings Call Transcript
Seeking Alpha05 August 2023 Sentiment: NEUTRAL

Chimerix, Inc. (NASDAQ:CMRX ) Q2 2023 Earnings Conference Call August 3, 2023 8:30 AM ET Company Participants Michelle Laspaluto - Vice President of Strategic Planning and Investor Relations Mike Andriole - President and CEO Josh Allen - Chief Technology Officer Allen Melemed - Chief Medical Officer Conference Call Participants Kevin Strang - Jefferies Naureen Quibria - Capital One Joel Beatty - Baird Ed White - H.C. Wainwright Soumit Troy - Jones Trading Joseph Thome - TD Cowen Operator Good morning, ladies and gentlemen, and welcome to the Chimerix Second Quarter 2023 Earnings Conference Call.

Chimerix: A High-Risk 'Lottery Ticket'
Seeking Alpha06 June 2023 Sentiment: POSITIVE

Today, we put the spotlight on Chimerix, Inc. for the first time in 12 months. The company is advancing its primary oncology candidate in development, has a potentially large market, and sells for less than net cash on its balance sheet. An updated investment analysis on Chimerix, Inc. follows in the paragraphs below.

What type of business is Chimerix?

Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.

What sector is Chimerix in?

Chimerix is in the Healthcare sector

What industry is Chimerix in?

Chimerix is in the Biotechnology industry

What country is Chimerix from?

Chimerix is headquartered in United States

When did Chimerix go public?

Chimerix initial public offering (IPO) was on 11 April 2013

What is Chimerix website?

https://www.chimerix.com

Is Chimerix in the S&P 500?

No, Chimerix is not included in the S&P 500 index

Is Chimerix in the NASDAQ 100?

No, Chimerix is not included in the NASDAQ 100 index

Is Chimerix in the Dow Jones?

No, Chimerix is not included in the Dow Jones index

When was Chimerix the previous earnings report?

No data

When does Chimerix earnings report?

The next expected earnings date for Chimerix is 28 February 2025